Cojutti P.G.; Carnelutti A.; Lazzarotto D.; Sozio E.; Candoni A.; Fanin R.; Tascini C.; Pea F., Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?, «PHARMACEUTICS», 2021, 13, Article number: 2099, pp. 1 - 13 [articolo]Open Access
Cojutti P.G.; Morandin E.; Baraldo M.; Pea F., Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 58, Article number: 106408, pp. 1 - 9 [articolo]
Cojutti, Pier Giorgio; Rinaldi, Matteo; Zamparini, Eleonora; Rossi, Nicolò; Tedeschi, Sara; Conti, Matteo; Pea, Federico; Viale, Pierluigi, Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2021, 65, Article number: e02260-20, pp. 1 - 12 [articolo]
Meschiari, Marianna; Volpi, Sara; Faltoni, Matteo; Dolci, Giovanni; Orlando, Gabriella; Franceschini, Erica; Menozzi, Marianna; Sarti, Mario; Del Fabro, Giovanni; Fumarola, Benedetta; Guarneri, Francesco; Lanza, Paola; Lorenzotti, Silvia; Saccani, Barbara; Signorini, Liana; Van Hauwermeiren, Evelyn; Gatti, Milo; Pea, Federico; Castelli, Francesco; Mussini, Cristina, Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections, «JAC-ANTIMICROBIAL RESISTANCE», 2021, 3, Article number: dlab188, pp. 1 - 5 [articolo]Open Access
Cojutti, Pier Giorgio; Zanon, Ezio; Pasca, Samantha; Pea, Federico, Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency, «CLINICAL PHARMACOKINETICS», 2021, na, pp. 1 - 12 [articolo]
Gatti M.; Andreoni M.; Pea F.; Viale P., Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs, «DRUG DESIGN, DEVELOPMENT AND THERAPY», 2021, 15, pp. 3349 - 3378 [articolo]Open Access
Gatti, Milo; Pea, Federico, Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections?, «CLINICAL PHARMACOKINETICS», 2021, 60, pp. 403 - 407 [articolo]
Gaibani, Paolo; Gatti, Milo; Rinaldi, Matteo; Crovara, Cristina; Lazzarotto, Tiziana; Giannella, Maddalena; Lombardo, Donatella; Amadesi, Stefano; Viale, Pierluigi; Pea, Federico; Ambretti, Simone, Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient, «INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES», 2021, 113, pp. 213 - 217 [articolo]Open Access
Wagenlehner, Florian; Lucenteforte, Ersilia; Pea, Federico; Soriano, Alex; Tavoschi, Lara; Steele, Victoria R; Henriksen, Anne Santerre; Longshaw, Christopher; Manissero, Davide; Pecini, Raymond; Pogue, Jason M, Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins, «CLINICAL MICROBIOLOGY AND INFECTION», 2021, 27, pp. 671 - 686 [articolo]Open Access
Andreoni M.; Bassetti M.; Corrao S.; De Rosa F.G.; Esposito V.; Falcone M.; Grossi P.; Pea F.; Petrosillo N.; Tascini C.; Venditti M.; Viale P., The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives, «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2021, 19, pp. 1125 - 1134 [articolo]
Sartelli M.; Ansaloni L.; Bartoletti M.; Catena F.; Cardi M.; Cortese F.; Di Marzo F.; Pea F.; Plebani M.; Rossolini G.M.; Sganga G.; Viaggi B.; Viale P., The role of procalcitonin in reducing antibiotics across the surgical pathway, «WORLD JOURNAL OF EMERGENCY SURGERY», 2021, 16, Article number: 15, pp. 1 - 9 [articolo]Open Access
Cojutti P.G.; Rinaldi M.; Gatti M.; Tedeschi S.; Viale P.; Pea F., Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 58, Article number: 106445, pp. 1 - 3 [articolo]
Barco S.; Mesini A.; Barbagallo L.; Maffia A.; Tripodi G.; Pea F.; Saffioti C.; Castagnola E.; Cangemi G., A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients, «JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS», 2020, 186, Article number: 113273, pp. 1 - 10 [articolo]
Sganga G.; Pea F.; Aloj D.; Corcione S.; Pierangeli M.; Stefani S.; Rossolini G.M.; Menichetti F., Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel, «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2020, 18, pp. 231 - 240 [articolo]
Bassetti M.; Vena A.; Bouza E.; Peghin M.; Munoz P.; Righi E.; Pea F.; Lackner M.; Lass-Florl C., Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?, «CLINICAL MICROBIOLOGY AND INFECTION», 2020, 26, pp. 1024 - 1033 [articolo]
